NASDAQ:SMMT Summit Therapeutics Q3 2026 Earnings Date & Estimates $17.59 +0.42 (+2.45%) Closing price 10/9/2026 04:00 PM EasternExtended Trading$17.60 +0.00 (+0.03%) As of 10/9/2026 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Summit Therapeutics is scheduled to report Q3 2026 earnings on Monday, October 19, 2026, before market opens. The conference call is scheduled for 8:00 AM ET. Research:ProfileEarnings HistoryForecast Upcoming Earnings Announcement QuarterQ3 2026Announcement DateOctober 19, 2026TimeBefore Market OpensConference Call8:00 AM ET Add to CalendarGoogle Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab) What Analysts Expect from Summit Therapeutics in Q3 2026Summit Therapeutics is expected to post earnings of -$0.28 per share on revenue of $0.07 million. In the same quarter a year earlier Summit Therapeutics reported -$0.31 per share. Summit Therapeutics last reported on July 23, 2026, posting -$0.28 per share and missing the -$0.2744 consensus estimate. Summit Therapeutics has beaten the consensus EPS estimate in 2 of its last 8 quarters.Consensus EstimatesConsensus EPS-$0.28Expected Revenue$0.07 millionPrior-Year EPS-$0.31Recent Track RecordLast ReportedQ2 2026Last Quarter EPS-$0.28 (Missed by -$0.0056)EPS Beat Rate2 of last 8 quartersPrepare for the Q3 2026 CallEarnings HistoryCompany ProfileQ2 2026 Earnings ReportQ1 2026 Earnings ReportQ4 2025 Earnings Report Summit Therapeutics Q3 2026 Earnings FAQ When does Summit Therapeutics report Q3 2026 earnings? Summit Therapeutics (NASDAQ:SMMT) is scheduled to report Q3 2026 earnings on Monday, October 19, 2026, before market opens. What time is Summit Therapeutics' Q3 2026 earnings call? Summit Therapeutics' Q3 2026 earnings conference call is scheduled for Monday, October 19, 2026 at 8:00 AM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date. What is the consensus EPS estimate for Summit Therapeutics? Analysts expect Summit Therapeutics to post earnings of -$0.28 per share for Q3 2026. How much revenue is Summit Therapeutics expected to report? The consensus revenue estimate for Summit Therapeutics is $0.07 million for Q3 2026. Summit Therapeutics Earnings HeadlinesSummit Therapeutics (SMMT) Is Up 7.3% After $2 Billion AstraZeneca Partnership and Trial CollaborationOctober 2, 2026 | finance.yahoo.comDaiichi Sankyo, AstraZenca, Summit Partner To Evaluate Datroway Plus IvonescimabOctober 2, 2026 | rttnews.comHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - but now he believes he's found something better. This under-the-radar company sits at the intersection of America's two most important industries, including AI, pays massive dividends, and attracted a famous money manager who put 60% of his multi-billion-dollar fund into it. Tilson is revealing the name and ticker symbol completely free - no credit card or email required.October 11 at 1:00 AM | Stansberry Research (Ad)Summit Therapeutics (NASDAQ:SMMT) Shares Climb 7.1% - Here's What HappenedOctober 2, 2026 | americanbankingnews.comSummit agrees to $2 billion AstraZeneca equity investmentOctober 2, 2026 | americanbankingnews.comSummit Therapeutics Announces Clinical Trial Collaboration with AstraZeneca and Daiichi Sankyo to Evaluate Ivonescimab in Combination with TROP2-Directed ADC DatrowayOctober 2, 2026 | businesswire.comSee More Summit Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Summit Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Summit Therapeutics and other key companies, straight to your email. Email Address About Summit TherapeuticsSummit Therapeutics (NASDAQ:SMMT) is a clinical-stage biopharmaceutical company focused on developing innovative cancer treatments. The company’s lead program is ivonescimab, an investigational bispecific antibody designed to combine immune checkpoint inhibition targeting PD-1 with anti-angiogenic activity targeting VEGF. Summit is evaluating ivonescimab in clinical studies for multiple solid tumors, including non-small cell lung cancer. Summit obtained exclusive rights from Akeso, Inc. to develop and commercialize ivonescimab in markets outside China, including the United States and other international territories. Akeso retains rights in China and certain related markets. The program is being advanced through clinical development and regulatory activities intended to assess its safety and effectiveness as a potential treatment for patients with cancer. Founded in the United Kingdom, Summit historically worked on therapies for infectious diseases, including the investigational antibiotic ridinilazole for Clostridioides difficile infection, before shifting its strategic focus to oncology. The company is led by Robert W. Duggan, who serves as chairman and chief executive officer. Summit Therapeutics is headquartered in Miami, Florida, and its ordinary shares trade on the Nasdaq under the symbol SMMT.View Summit Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 10/05 - 10/09Q3 Earnings Could Blow Past Consensus—Be Ready for What Comes NextDelta Air Lines Faces a Fuel Crisis—But There's a Silver LiningPalantir’s Rally Puts Wall Street in Catch-Up Mode Ahead of November EarningsApplied Digital’s Hidden Moat Could Unlock Massive UpsideLevi's Stock Dip Reveals Value Opportunity Despite Q3 HeadwindsTilray Finds a Path to Growth Without Waiting on U.S. Cannabis Reform Upcoming Earnings Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026)BlackRock (10/14/2026)Morgan Stanley (10/14/2026)Progressive (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
